Millennium Withdraws Velcade Follicular Lymphoma sNDA, Citing Business Decision
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
It appears the burden of serious adverse events was too much to justify the 1.8 month survival benefit conferred by the addition of Millennium’s Velcade (bortezomib) to Roche’s Rituxan (rituximab) in patients with relapsed follicular lymphoma.